Dignify Therapeutics is focused on restoring voluntary control of bowel and bladder function, with our beachhead market in spinal cord injury (SCI). Two-thirds of SCI people require insertion of someone’s fingers into the rectum with stroking of the mucosa for 1-2 hours to defecate and insertion of catheters through the penis or vagina to urinate. The ability to control bowel and bladder function is more important to people with SCI than regaining the ability to walk. The extended market includes institutionalized elderly and those with other neurological diseases. These populations are recognized by third-party payors as representing a severe, unmet medical need, which should gain us Fast-track approval from the FDA with peak annual sales of ~$1B/year. The halo market includes people with idiopathic constipation and urinary retention. Dignify has a robust development pipeline with 3 projects ready for IND-enabling studies and 2 preclinical projects that are also NIH funded.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):